Elsevier Launches Updated DDIRC
Elsevier, together with Boehringer Ingelheim, Eli Lilly and Company, Pierre Fabre, Sanofi, Servier and others, has further extended its drug-drug interaction risk calculator (DDIRC) within PharmaPendium. The DDIRC 2.0 aims to help scientists improve patient safety and effectively manage drug-drug interaction (DDI) risks across the drug development process.
The tool enables researchers to track predictions through the development cycle from pre-clinical to phase III trials and project manage multiple simulations at the same time. It also assists with inclusion and exclusion criteria for patients in phase II and III trials.
For more information, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
